Sanofi: new data presented on Dupixent
(CercleFinance.com) - Twenty-five scientific abstracts evaluating Dupixent (dupilumab) in moderate-to-severe atopic dermatitis from childhood to adulthood, nodular prurigo and chronic spontaneous urticaria will be presented at the European Academy of Dermatology and Venereology (EADV) 2022 Congress from 7 to 10 September.
These data add to a growing body of clinical and real-world evidence illustrating the potential benefit of Dupixent.
New analyses from the pivotal trial in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis will be presented in eight posters.
Data from patients with moderate to severe atopic dermatitis aged 6 years and older will also be presented as well as recent results from a Phase 3 trial of dupilumab showing improvement in signs and symptoms in adults with nodular prurigo.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
These data add to a growing body of clinical and real-world evidence illustrating the potential benefit of Dupixent.
New analyses from the pivotal trial in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis will be presented in eight posters.
Data from patients with moderate to severe atopic dermatitis aged 6 years and older will also be presented as well as recent results from a Phase 3 trial of dupilumab showing improvement in signs and symptoms in adults with nodular prurigo.
Copyright (c) 2022 CercleFinance.com. All rights reserved.